Advanced search
Add to list

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease : results from a single-centre cohort

(2009) GUT. 58(4). p.492-500
Author
Organization
Abstract
Background and aims: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). Methods: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. Results: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. Conclusions: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.
Keywords
INFLAMMATORY-BOWEL-DISEASE, FOLLOW-UP, EPISODIC TREATMENT, MAINTENANCE, 6-MERCAPTOPURINE, AZATHIOPRINE, METHOTREXATE, DEPENDENCY, THERAPY, PLACEBO

Citation

Please use this url to cite or link to this publication:

MLA
Schnitzler, F., et al. “Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease : Results from a Single-Centre Cohort.” GUT, vol. 58, no. 4, 2009, pp. 492–500.
APA
Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., … Rutgeerts, P. (2009). Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease : results from a single-centre cohort. GUT, 58(4), 492–500.
Chicago author-date
Schnitzler, F, H Fidder, M Ferrante, M Noman, I Arijs, G Van Assche, I Hoffman, Kristel Van Steen, S Vermeire, and P Rutgeerts. 2009. “Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease : Results from a Single-Centre Cohort.” GUT 58 (4): 492–500.
Chicago author-date (all authors)
Schnitzler, F, H Fidder, M Ferrante, M Noman, I Arijs, G Van Assche, I Hoffman, Kristel Van Steen, S Vermeire, and P Rutgeerts. 2009. “Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease : Results from a Single-Centre Cohort.” GUT 58 (4): 492–500.
Vancouver
1.
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease : results from a single-centre cohort. GUT. 2009;58(4):492–500.
IEEE
[1]
F. Schnitzler et al., “Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease : results from a single-centre cohort,” GUT, vol. 58, no. 4, pp. 492–500, 2009.
@article{5907165,
  abstract     = {Background and aims: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). 
Methods: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. 
Results: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. 
Conclusions: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.},
  author       = {Schnitzler, F and Fidder, H and Ferrante, M and Noman, M and Arijs, I and Van Assche, G and Hoffman, I and Van Steen, Kristel and Vermeire, S and Rutgeerts, P},
  issn         = {0017-5749},
  journal      = {GUT},
  keywords     = {INFLAMMATORY-BOWEL-DISEASE,FOLLOW-UP,EPISODIC TREATMENT,MAINTENANCE,6-MERCAPTOPURINE,AZATHIOPRINE,METHOTREXATE,DEPENDENCY,THERAPY,PLACEBO},
  language     = {eng},
  number       = {4},
  pages        = {492--500},
  title        = {Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease : results from a single-centre cohort},
  url          = {http://dx.doi.org/10.1136/gut.2008.155812},
  volume       = {58},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: